• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Remote Monitoring Won’t Require Post-Pandemic “Re-Monitoring,” FDA Says

Remote Monitoring Won’t Require Post-Pandemic “Re-Monitoring,” FDA Says

August 3, 2020

The FDA considers risk-based remote monitoring conducted during the COVID-19 crisis to be sufficient and will not ask sponsors to re-monitor all data after the pandemic passes, but sponsors themselves may choose to do so, two agency officials say.

Jean Mulinde of the FDA’s Division of Clinical Compliance Evaluation reiterated the agency’s support of risk-based monitoring — remote or not — at a Drug Information Association webinar last week, but advised sites and CROs to discuss the possibility of a follow-up source data verification (SDV) effort with their sponsors.

Mulinde recommended sites, CROs and sponsors work together to determine whether redacted source documents used for remote monitoring during the pandemic will eventually require re-monitoring with certified documentation once on-site monitoring resumes.

Alyson Karesh, director of the FDA’s Division of Clinical Trial Quality, Office of Medical Policy, advised webinar attendees to keep the big picture in mind. “Part of the whole reason to do a risk-based approach is to prioritize,” Karesh said. “SDV or SDR (source data review) may or may not be a good thing to do depending upon the situation. It isn’t necessarily prioritized and it’s not necessarily risk-based.”

But Mulinde, citing previous experience from a compliance perspective, warned that under a 100 percent SDV model, “monitors will then miss really important things because they’re overly focused on transcription checking.”

Speaking from the sponsor point of view, Jackie Gough, director for centralized monitoring and data surveillance at Astellas Pharma, agreed that SDV is not as effective as focusing monitoring efforts on priority issues. “We simply don’t feel that transcription checking is getting us enough value.”

Astellas has no predefined requirement for follow-up monitoring, Gough said, “But if a site monitor discovered something at the site that would indicate to them that the site doesn’t know how to complete the CRFs [case report forms] correctly [or] doesn’t know how to do that transcribing appropriately, nothing prevents (the monitor) from going and doing a spot check of that activity.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing